| Objective: to study whether there are differences in the control of disease progression in patients with metastatic hormone-sensitive prostate cancer(mHSPC)treated with different doses of goserelin sustained-release implants,and to study the relationship between serum testosterone level after regular endocrine therapy and disease progression in patients with mHSPC.Methods:A retrospective analysis was made on 151 patients with mHSPC from January 2014 to September 2019.these patients were pathologically diagnosed by prostate biopsy in our hospital and were proved to be mHSPC by imaging data.To study whether there was any difference in the relationship between regular exposure to different dosage forms of goserelin and the time of progression to castrated resistant prostate cancer(CRPC).And to study the relationship between serum testosterone level and CRPC time in patients receiving endocrine therapy of goserelin combined with bicalutamide,and to further verify the correlation between testosterone and disease progression in patients with mHSPC.Kaplan-Meier survival analysis and COX regression analysis were performed with R software.Results:There was no statistical difference in the time of disease progression to CRPC between different dosage forms(3.6mg and 10.8mg)of goserelin sustained-release implants combined with bicalutamide(P>0.05).The nadir testosterone(NT)? 0.70nmol/L during endocrine therapy is a protective factor affecting the time of progression to CRPC.After the serum testosterone level reached the castrated level,the longer time to nadir testosterone(TTNT),the slower the disease progressed to CRPC.Conclusion:There is no significant difference in the effect of different dosage forms(10.8mg and 3.6mg)on the progression of the disease to CRPC.The lower the NT control and the longer the TTNT in patients with mHSPC,the longer the progression of prostate cancer to CRPC. |
PDF Full Text Request